Copyright
©The Author(s) 2018.
World J Gastroenterol. Dec 14, 2018; 24(46): 5288-5296
Published online Dec 14, 2018. doi: 10.3748/wjg.v24.i46.5288
Published online Dec 14, 2018. doi: 10.3748/wjg.v24.i46.5288
Table 1 Comparative baseline demographics and phenotypic characteristics of patients with Crohn's disease and ulcerative colitis in both groups n (%)
| Prospective cohort | 95%CI | Retrospective cohort | 95%CI | P value | ||
| Characteristics (n = 98) | ||||||
| Sex | men | 51 (52) | 41.6-62.4 | 56 (57.1) | 46.8-67.4 | |
| women | 47 (48) | 37.6-58.4 | 42 (42.9) | 32.5-53.2 | 0.280 | |
| Smoking status | Never | 67 (68.3) | 58.7-78.1 | 69 (70.4) | 60.9-79.9 | |
| Previous | 18 (18.4) | 10.2-26.5 | 16 (16.3) | 8.5-24.1 | 0.929 | |
| Current | 13 (13.3) | 6.0-20.5 | 13 (13.3) | 6.1-20.5 | ||
| Crohn’s disease (n = 67) | ||||||
| Age at diagnosis | A1 (< 17) | 7 (10.5) | 2.4-18.5 | 10 (15) | 5.6-24.2 | |
| A2 (17-40) | 49 (73.1) | 61.8-84.5 | 48 (71.6) | 60.1; 83.2 | 0.691 | |
| A3 ( > 40) | 11 (16.4) | 6.8-26.0 | 9 (13.4) | 4.5; 22.3 | ||
| Location at diagnosis | L1 (ileal) | 18 (26.9) | 15.5-38.2 | 15 (22.4) | 11.7-33.1 | |
| L2 (colonic) | 26 (38.8) | 26.4-51.2 | 25 (37.3) | 25.0-49.6 | 0.887 | |
| L3 (ileocolonic) | 21 (31.3) | 19.5-43.2 | 25 (37.3) | 25.0-49.6 | ||
| L4 (upper gastrointestinal tract) | 2 (3.0) | 0.3-10.4 | 2 (3.0) | 0.4-10.4 | ||
| Disease behavior | B1 (non-stricturing, non-penetrating) | 38 (56.7) | 44.169.3 | 39 (58.2) | 45.7-70.8 | 0.860 |
| B2 (stricturing) | 14 (20.9) | 10.4-31.4 | 13 (19.4) | 9.2-29.6 | ||
| B3 (penetrating) | 15 (22.4) | 11.7-33.1 | 15 (22.4) | 11.7-33.1 | ||
| Perianal disease | Yes | 37 (55.2) | 42.6-67.9 | 39 (58.2) | 45.7-70.8 | 0.727 |
| Extraintestinal manifestations | No | 42 (62.7) | 50.4-75.0 | 46 (68.7) | 56.8-80.5 | 0.466 |
| Ulcerative colitis (n = 31) | ||||||
| Extension | ||||||
| E1 (proctitis) | 13 (41.9) | 22.9-60.9 | 12 (38.7) | 19.9-57.5 | ||
| E2 (left colitis) | 10 (32.3) | 14,2-50.3 | 11 (35.5) | 17.0-53.9 | 0.957 | |
| E3 (pancolitis) | 8 (25.8) | 8.8-42.9 | 8 (25.8) | 8.8-42.9 | ||
| Severity | S1 (mild) | 11 (35.5) | 17.0-53.9 | 10 (32.3) | 14.2-50.3 | |
| S2 (moderate) | 16 (51.6) | 32.4-70.8 | 17 (54.8) | 35.7-74.0 | 0.962 | |
| S3 (severe) | 4 (12.9) | 3.6-29.8 | 4 (12.9) | 3.6-29.8 | ||
| Extraintestinal manifestations | No | 26 (83.9) | 66.3-94.5 | 27 (87.1) | 66.3-94.5 | 0.500 |
| Prior treatment | 75 (76.5) | 67.6-85.4 | 85 (86.7) | 79.5-94 | 0.097 | |
| Thiopurines | 25 (25.5) | 16.4-34.7 | 25 (25.5) | 16.4-34.7 | 0.970 | |
| Methotrexate | ||||||
| Concomitant treatment | 50 (51) | 40.6-61.4 | 40 (40.8) | 30.6-51.1 | 0.197 | |
| Thiopurines | 8 (8) | 2.2-14.1 | 7 (7,1) | 1.1-10,1 | 0.999 | |
| Methotrexate | ||||||
- Citation: Guerra Veloz MF, Argüelles-Arias F, Castro Laria L, Maldonado Pérez B, Benítez Roldan A, Perea Amarillo R, Merino Bohórquez V, Calleja MA, Caunedo Álvarez Á, Vilches Arenas Á. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. World J Gastroenterol 2018; 24(46): 5288-5296
- URL: https://www.wjgnet.com/1007-9327/full/v24/i46/5288.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i46.5288